Answers are grounded in this paper and cite their sources.
Purpose: To report a refractory secondary retinal vasoproliferative tumor (RVPT) associated with congenital toxoplasmosis in a monocular pediatric patient and discuss timing of therapeutic escalation. Methods: Longitudinal follow-up with multimodal imaging in a 13-year-old monocular patient with congenital toxoplasmosis who developed a progressive RVPT unresponsive to sequential therapies, including six intravitreal bevacizumab injections, three intravitreal aflibercept injections, one laser photocoagulation session, and one cryotherapy session. Treatment was escalated to four every-other-week intravitreal faricimab injections and, subsequently, single-session iodine-125 plaque brachytherapy. Results: Every-other-week faricimab produced a significant reduction in tumor activity and exudation, and brachytherapy achieved durable tumor regression; allowing progressive extension of the anti-VEGF and visual acuity preservation (20/25 at presentation, 20/30 at last follow-up). Conclusion: Secondary RVPT associated with congenital toxoplasmosis may be highly treatment-refractory. In cases with progressive activity and risk to central vision, particularly in monocular patients, earlier consideration of brachytherapy may be warranted.
No takes yet. Share an insight, caveat, or question.
Sabage et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: